UniProtKB/Swiss-Prot O97980: Variant p.His16Tyr

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 16 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LB/B The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Histidine (H) to Tyrosine (Y) at position 16 (H16Y, p.His16Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from medium size and polar (H) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In allele HB-1Y; loss of CTL recognition for epitope HB-1. No influence on HLA-B/HLA-B44 binding, nor on the processing by the proteasome. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs161557 [ dbSNP | Ensembl ]

Sequence information

Variant position: 16 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 41 The length of the canonical sequence.
Location on the sequence: MEEQPECREEKRGSL H VWKSELVEVEDDVYLRHSSS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 41	Minor histocompatibility protein HB-1
Peptide	9 – 18	Minor histocompatibility antigen HB-1
Region	9 – 17	Loss of recognition by cytotoxic T lymphocyte (CTL)
Mutagenesis	9 – 9	E -> A. Decreased CTL recognition.
Mutagenesis	10 – 10	E -> A. Decreased CTL recognition.
Mutagenesis	11 – 11	K -> A. Complete loss of CTL recognition.
Mutagenesis	12 – 12	R -> A. Complete loss of CTL recognition.
Mutagenesis	13 – 13	G -> A. Complete loss of CTL recognition.
Mutagenesis	14 – 14	S -> A. Complete loss of CTL recognition.
Mutagenesis	15 – 15	L -> A. Complete loss of CTL recognition.
Mutagenesis	16 – 16	H -> A. Complete loss of CTL recognition.
Mutagenesis	16 – 16	H -> R. CTL recognition.
Mutagenesis	17 – 17	V -> A. Decreased CTL recognition.
Mutagenesis	18 – 18	W -> A. Complete loss of CTL recognition.

Literature citations

A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.
Dolstra H.; Fredrix H.; Maas F.; Coulie P.G.; Brasseur F.; Mensink E.; Adema G.J.; de Witte T.M.; Figdor C.G.; van de Wiel-van Kemenade E.;
J. Exp. Med. 189:301-308(1999)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; PROTEIN SEQUENCE OF 9-18; TISSUE SPECIFICITY; FUNCTION; VARIANT TYR-16;